6.74
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
ABEONA THERAPEUTICS Executives Sell Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics Officer Sells Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade) - Seeking Alpha
Abeona Therapeutics at Jefferies Conference: ZivaSkin’s Promising Launch By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Gains "Outperform" Rating from Oppenheimer | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating with Promising Outlook | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating - GuruFocus
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics Announces New Employee Inducement Grants - marketscreener.com
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Un - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics Awards Stock Grants Worth 11,500 Shares: New Employee Compensation Details Revealed - Stock Titan
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Abeona Therapeutics® to Present at the Jefferies Global Healthca - GuruFocus
Abeona Therapeutics Inc. CEO and CCO to Speak at Jefferies Global Healthcare Conference on June 4, 2025 - Nasdaq
Abeona Therapeutics Leadership to Share Latest Company Updates at Major Healthcare Conference - Stock Titan
Trading (ABEO) With Integrated Risk Controls - news.stocktradersdaily.com
Director Cashes In on Abeona Therapeutics Stock! - TipRanks
Insider Sell: Mark Alvino Sells Shares of Abeona Therapeutics In - GuruFocus
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionAbeona Therapeutics (NASDAQ:ABEO), Ascentage Pharma Group (NASDAQ:AAPG) - Benzinga
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - Benzinga
ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight - PR Newswire
Dystrophic Epidermolysis Bullosa Market Predicted to See - openPR.com
ABEO: Sells Priority Review Voucher for $155 Million… - MSN
Abeona Therapeutics finally expanding to make cell-based gene therapy - The Business Journals
Abeona Therapeutics Elects New Directors at Meeting - TipRanks
ABEO: Sells Priority Review Voucher for 155 Million - Smartkarma
Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway - MSN
Stifel Nicolaus Issues Pessimistic Forecast for Abeona Therapeutics (NASDAQ:ABEO) Stock Price - Defense World
(ABEO) Trading Report - news.stocktradersdaily.com
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2025 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Lowered by StockNews.com - Defense World
Stifel cuts Abeona Therapeutics price target to $20, maintains Buy By Investing.com - Investing.com South Africa
Abeona Therapeutics Reports Improved Financial Performance - TipRanks
Insider Selling: Mark Alvino Sells Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics (ABEO) Transitions to Commercial Stage with ZEVASKYN Launch - GuruFocus
Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success - TipRanks
Stifel cuts Abeona Therapeutics price target to $20, maintains Buy - Investing.com Australia
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO St - GuruFocus
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Receives Revised Price Target Amid Po - GuruFocus
Abeona Therapeutics: Q1 Earnings Snapshot - CT Insider
Earnings call transcript: Abeona Therapeutics beats EPS forecast in Q1 2025 - Investing.com Nigeria
Abeona Therapeutics (ABEO) Target Price Raised Following FDA Approval and Strategic Sale | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Exceeds EPS Estimates, Bolstered by S - GuruFocus
ABEO Shows Decrease in Cash Reserves Before PRV Sale Completion - GuruFocus
Abeona Therapeutics (ABEO) Launches ZEVASKYN, A Milestone in Gen - GuruFocus
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates | ABEO Stock News - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):